2nd September 2008
Evotec and Boehringer Ingelheim Achieve Milestone in Joint Discovery Collaboration
Evotec AG today announced that a third milestone has been successfully achieved in their collaboration with Boehringer Ingelheim.
Read this article
11th August 2008
Cortria Appoints Dr. Gene Cefali as SVP Clinical Pharmacology & Formulation Development
Cortria Corporation announces the appointment of Gene Cefali, Pharm.D., Ph.D., a globally recognised niacin metabolism and pharmacokinetics expert, as Senior Vice President of Clinical Pharmacology and Formulation Development.
Read this article
14th July 2008
Cortria Announces Appointment of CEO & Director
Domain Associates & MVM today announced the appointment of Daniel Grau as CEO & Vice-Chairman and Richard King as Director of Cortria.
Read this article
5th May 2008
Evotec Completes Acquisition of Renovis
Evotec AG announced that the merger has been successfully completed and that Renovis, Inc. is a wholly owned subsidiary of Evotec as of May 5, 2008.
Read this article
25th March 2008
Oxford BioMedica Report Encouraging New Phase II Trial Results with Trovax® in Prostate Cancer
Oxford BioMedica, a leading gene therapy company, announces encouraging new data from its first Phase II trial of TroVax in prostate cancer.
Read this article
News Archive
Last 5 Articles | Next 5 Articles
2nd September 2008Evotec and Boehringer Ingelheim Achieve Milestone in Joint Discovery Collaboration
Hamburg, Germany – Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today announced that a third milestone has been successfully achieved in their collaboration with Boehringer Ingelheim. Under the terms of the drug discovery contract, Evotec will receive a milestone payment from Boehringer Ingelheim which was granted for the selection of an advanced compound for profiling to enable the start of preclinical development.
Further projects within the multi-target collaboration are progressing and are on track to achieve additional project milestones for which Evotec is entitled to receive additional payments from Boehringer Ingelheim. Furthermore, the contract provides substantial long-term upside through potential payments for successful milestone achievements during clinical development and royalties when new drugs reach the market. Further financial details of the payment were not disclosed.
Dr John Kemp, Chief Research and Development Officer at Evotec, commented: “We are proud to have achieved this important milestone in one of our projects with Boehringer Ingelheim. This further demonstrates our capabilities to discover novel drugs based on our drug discovery expertise. Our collaboration with Boehringer Ingelheim is progressing very well and we are looking forward to continued success.”
| Associated Links Visit Evotec AG |
Downloads Full Press Release |